Functional_JJ group_NN interactions_NNS of_IN a_DT 5-HT3R_NP antagonist_NN Abstract_NP |_SYM Background_NN |_SYM Lerisetron_NP ,_, a_DT competitive_JJ serotonin_NN type_NN 3_CD receptor_NN (_( 5-HT3R_NP )_) antagonist_NN ,_, contains_VBZ five_CD functional_JJ groups_NNS capable_JJ of_IN interacting_VBG with_IN amino_NN acids_NNS in_IN the_DT 5-HT3R_NP binding_JJ site_NN ._SENT Site_NN directed_VBD mutagenesis_NN studies_NNS of_IN the_DT 5-HT3AR_NP have_VBP revealed_VBN several_JJ amino_NN acids_NNS that_WDT are_VBP thought_VBN to_TO form_VB part_NN of_IN the_DT binding_JJ domain_NN of_IN this_DT receptor_NN ._SENT The_DT specific_JJ functional_JJ groups_NNS on_IN the_DT ligand_NN that_WDT interact_VBP with_IN these_DT amino_NN acids_NNS are_VBP ,_, however_RB ,_, unknown_JJ ._SENT Using_VBG synthetic_JJ analogs_NNS of_IN lerisetron_NN as_IN molecular_JJ probes_NNS in_IN combination_NN with_IN site_NN directed_VBN mutagenesis_NN ,_, we_PP have_VBP identified_VBN some_DT of_IN these_DT interactions_NNS and_CC have_VBP proposed_VBN a_DT model_NN of_IN the_DT lerisetron_NN binding_VBG site_NN ._SENT Results_NNS |_SYM Two_NP analogs_NNS of_IN lerisetron_NN were_VBD synthesized_VBN to_TO probe_VB 5-HT3R_NP functional_JJ group_NN interactions_NNS with_IN this_DT compound_NN ._SENT Analog_NN 1_CD lacks_VBZ the_DT N1_JJ benzyl_NN group_NN of_IN lerisetron_NN and_CC analog_JJ 2_CD contains_VBZ oxygen_NN in_IN place_NN of_IN the_DT distal_JJ piperazine_NN nitrogen_NN ._SENT Both_DT analogs_NNS show_VBP significantly_RB decreased_VBN binding_JJ affinity_NN to_TO wildtype_NN 5-HT3ASRs_NN ._SENT Mutations_NNS at_IN W89_NP ,_, R91_NP ,_, Y142_NP and_CC Y152_NP produced_VBD significant_JJ decreases_NNS in_IN binding_VBG compared_VBN to_TO wildtype_NN receptors_NNS ._SENT Binding_JJ affinities_NNS of_IN analogs_NNS 1_CD and_CC 2_CD were_VBD altered_VBN only_RB by_IN mutations_NNS at_IN W89_NP ,_, and_CC Y152_NP ._SENT Conclusions_NNS |_SYM Based_VBN on_IN the_DT data_NNS obtained_VBN for_IN lerisetron_NN and_CC analogs_NNS 1_CD and_CC 2_CD ,_, we_PP have_VBP proposed_VBN a_DT tentative_JJ model_NN of_IN the_DT lerisetron_NN binding_VBG pocket_NN of_IN the_DT 5-HT3ASR_NN ._SENT According_VBG to_TO this_DT model_NN ,_, The_DT N-benzyl_NP group_NN interacts_VBZ in_IN a_DT weak_JJ interaction_NN with_IN R91_NP while_IN the_DT benzimidazole_NN group_NN interacts_VBZ with_IN W89_NP ._SENT Our_PP$ data_NNS support_VBP an_DT interaction_NN of_IN the_DT distal_JJ amino_NN nitrogen_NN with_IN Y142_NP and_CC Y152_NP ._SENT The_DT cysteine-loop_NN family_NN of_IN ligand_NN gated_VBD ion_NN channels_NNS (_( LGIC_NP )_) is_VBZ comprised_VBN of_IN receptors_NNS with_IN pentameric_JJ quaternary_JJ structure_NN and_CC at_IN least_JJS two_CD ligand_NN binding_JJ sites_NNS present_JJ at_IN the_DT subunit_NN interfaces_NNS ._SENT This_DT receptor_NN family_NN is_VBZ characterized_VBN by_IN the_DT presence_NN of_IN a_DT critical_JJ disulfide_NN loop_NN structure_NN within_IN the_DT binding_JJ site_NN and_CC an_DT integral_JJ ion_NN selective_JJ channel_NN ._SENT LGIC_JJ receptors_NNS are_VBP found_VBN in_IN both_CC the_DT peripheral_JJ and_CC central_JJ nervous_JJ systems_NNS ._SENT Members_NNS of_IN this_DT family_NN include_VBP the_DT acetylcholine_NN receptors_NNS ,_, the_DT gamma-amino_NN butyric_JJ acid_NN type_NN A_DT receptor_NN (_( GABAAR_NP )_) ,_, and_CC the_DT glycine_NN receptor_NN (_( GlyR_NP )_) ._SENT The_DT first_JJ subunit_NN of_IN the_DT 5-HT3R_NN was_VBD cloned_VBN in_IN 1991_CD ._SENT The_DT sequence_NN of_IN this_DT subunit_NN was_VBD shown_VBN to_TO be_VB highly_RB homologous_JJ to_TO LGIC_JJ receptors_NNS and_CC thus_RB identified_VBN the_DT 5-HT3R_NN receptor_NN as_IN another_DT member_NN of_IN this_DT superfamily_NN ._SENT Similar_JJ to_TO other_JJ LGIC_JJ receptors_NNS ,_, more_JJR than_IN one_CD subtype_NN has_VBZ been_VBN identified_VBN ._SENT Two_CD splice_NN variants_NNS of_IN an_DT A_NP subunit_NN (_( long_JJ and_CC short_JJ forms_NNS )_) ,_, and_CC a_DT single_JJ B_NP subunit_NN have_VBP been_VBN cloned_VBN ._SENT Both_CC the_DT long_JJ and_CC short_JJ forms_NNS of_IN the_DT A_NP subunit_NN are_VBP capable_JJ of_IN forming_VBG functional_JJ homomeric_JJ receptors_NNS [_SYM 5-HT3ALR_NN and_CC 5-HT3ASR_NN ]_SYM although_IN some_DT differences_NNS between_IN an_DT agonist_NN and_CC partial_JJ agonist_NN activity_NN have_VBP been_VBN observed_VBN ._SENT A_DT third_JJ subtype_NN is_VBZ formed_VBN by_IN a_DT combination_NN of_IN the_DT A_NP and_CC B_NP subunits_NN to_TO produce_VB a_DT heteromeric_JJ receptor_NN of_IN unknown_JJ stoichiometry_NN ._SENT Heteromeric_JJ receptors_NNS are_VBP pharmacologically_RB and_CC functionally_RB distinct_JJ from_IN the_DT homomeric_JJ 5-HT3AL_JJ and_CC 5-HT3AS_JJ receptors_NNS ._SENT 5-HT3Rs_JJ are_VBP distributed_VBN throughout_IN the_DT central_JJ and_CC peripheral_JJ nervous_JJ system_NN ,_, playing_VBG a_DT significant_JJ role_NN in_IN phenomenon_NN such_JJ as_IN anxiety_NN ,_, emesis_NN and_CC alcoholism_NN ._SENT Antagonists_NNS to_TO 5-HT3Rs_NN are_VBP clinically_RB efficacious_JJ in_IN the_DT treatment_NN of_IN chemotherapy-induced_JJ emesis_NN and_CC recent_JJ studies_NNS on_IN human_JJ subjects_NNS have_VBP suggested_VBN their_PP$ potential_JJ application_NN in_IN the_DT treatment_NN of_IN early_JJ onset_NN alcoholism_NN ._SENT Hibert_NP et_FW al_NP proposed_VBD an_DT early_JJ model_NN for_IN the_DT antagonist_NN pharmacophore_NN of_IN the_DT 5-HT3R_NN ._SENT According_VBG to_TO this_DT model_NN ,_, all_DT 5-HT3R_NP antagonists_NNS contain_VBP an_DT aromatic_JJ ring_NN ,_, a_DT carbonyl_NN oxygen_NN or_CC bioisosteric_JJ equivalent_NN ,_, and_CC a_DT basic_JJ nitrogen_NN ._SENT According_VBG to_TO Hibert_NP 's_POS model_NN ,_, the_DT basic_JJ nitrogen_NN is_VBZ located_VBN 5.2A_NN from_IN the_DT centre_NN of_IN the_DT aromatic_JJ ring_NN and_CC approximately_RB 1.7A_JJ above_IN plane_NN of_IN the_DT ring_NN ._SENT The_DT carbonyl_NN oxygen_NN and_CC the_DT aromatic_JJ ring_NN are_VBP coplanar_JJ and_CC separated_VBN by_IN a_DT distance_NN of_IN 3.3A_NP ._SENT Recent_JJ studies_NNS have_VBP expanded_VBN on_IN this_DT model_NN to_TO include_VB another_DT lipophilic_JJ region_NN and_CC a_DT second_JJ hydrogen_NN bonding_VBG interaction_NN two_CD atoms_NNS away_RB from_IN the_DT first_JJ ._SENT A_DT compound_NN that_WDT contains_VBZ all_DT five_CD pharmacophoric_JJ regions_NNS was_VBD synthesized_VBN by_IN Orjales_NP et_FW al._FW This_DT compound_JJ (1-(phenylmethyl)-2-piperizinyl_NN benzimidazole_NN or_CC lerisetron_NN )_) is_VBZ shown_VBN in_IN figure_NN and_CC is_VBZ a_DT potent_JJ 5-HT3R_NN antagonist_NN ._SENT Functional_JJ groups_NNS on_IN this_DT compound_NN capable_JJ of_IN forming_VBG interactions_NNS with_IN the_DT receptor_NN are_VBP the_DT distal_JJ amino_NN group_NN ,_, a_DT benzimidazole_NN and_CC a_DT benzyl_NN group_NN in_IN the_DT N1_JJ position_NN of_IN the_DT benzimidazole_NN ._SENT While_IN Lerisetron_NP contains_VBZ no_DT carbonyl_NN group_NN ,_, the_DT second_JJ nitrogen_NN contained_VBN in_IN the_DT benzimidazole_NN heterocycle_NN could_MD act_VB as_IN bioisostere_NN of_IN this_DT functional_JJ group_NN ._SENT Orjales_NP demonstrated_VBD the_DT importance_NN of_IN the_DT N-benzyl_NP group_NN by_IN synthesizing_VBG several_JJ N1_JJ substituted_VBN analogs_NNS of_IN Lerisetron_NP ._SENT Removal_NN of_IN the_DT N-benzyl_NP group_NN produced_VBD a_DT 80-fold_JJ decrease_NN in_IN affinity_NN ,_, indicating_VBG a_DT role_NN for_IN this_DT group_NN in_IN interacting_VBG with_IN the_DT 5-HT3R_NN ._SENT Other_JJ studies_NNS have_VBP supported_VBN this_DT observation_NN and_CC suggest_VB a_DT more_RBR specific_JJ electrostatic_JJ interaction_NN ._SENT Figure_NP 1_CD |_SYM 5-HT3R_NN antagonists_NNS ._SENT 5-HT3R_NP antagonists_NNS ._SENT Granisetron_NP and_CC Lerisetron_NP are_VBP shown_VBN along_RP with_IN the_DT two_CD analogs_NNS utilized_VBN to_TO probe_VB the_DT functional_JJ group_NN interactions_NNS of_IN binding_JJ site_NN amino_NN acids_NNS ._SENT Analog_NN 1_CD lacks_VBZ the_DT N-benzyl_NP functional_JJ group_NN ._SENT Analog_NN 2_CD contains_VBZ oxygen_NN in_IN place_NN of_IN the_DT distal_JJ piperazine_NN nitrogen_NN ._SENT While_IN structure-activity_NN relationship_NN studies_NNS and_CC molecular_JJ modeling_NN have_VBP led_VBN to_TO the_DT development_NN of_IN a_DT detailed_JJ pharmacophore_NN model_NN ,_, determining_VBG specific_JJ point_NN interactions_NNS between_IN 5-HT3_JJ antagonists_NNS and_CC binding_JJ site_NN amino_NN acids_NNS has_VBZ proven_VBN difficult_JJ ._SENT Mutagenesis_NN studies_NNS have_VBP identified_VBN the_DT interaction_NN of_IN amino_NN acids_NNS W89_NP and_CC R91_NP in_IN the_DT binding_NN of_IN 5-HT3R_NN ligands_NNS ._SENT Studies_NNS conducted_VBN in_IN our_PP$ laboratory_NN have_VBP identified_VBN three_CD additional_JJ putative_JJ binding_JJ site_NN residues_NNS (_( Y140_NP ,_, Y142_NP ,_, and_CC Y152_NP )_) ._SENT W89_NP and_CC R91_NP are_VBP present_JJ in_IN a_DT conserved_VBN region_NN of_IN LGIC_JJ receptors_NNS often_RB referred_VBD to_TO as_RB loop_VB D_NP ._SENT Similarly_RB ,_, Y140_NP ,_, Y142_NP and_CC Y152_NP are_VBP located_VBN in_IN the_DT region_NN homologus_NN to_TO E_NP loop_NN region_NN of_IN nicotinic_JJ AchR_NP ._SENT In_IN this_DT study_NN ,_, we_PP have_VBP endeavoured_VBN to_TO identify_VB the_DT amino_NN acids_NNS interacting_VBG with_IN the_DT different_JJ functional_JJ groups_NNS present_JJ on_IN the_DT lerisetron_NN molecule_NN in_IN order_NN to_TO develop_VB a_DT model_NN for_IN interaction_NN of_IN this_DT compound_NN with_IN the_DT 5-HT3R_NN ._SENT Using_VBG site_NN directed_VBD mutagenesis_NN in_IN combination_NN with_IN analogs_NNS of_IN lerisetron_NN ,_, we_PP have_VBP identified_VBN amino_NN acids_NNS that_WDT appear_VBP to_TO interact_VB selectively_RB with_IN the_DT terminal_JJ amino_NN group_NN ,_, the_DT N-benzyl_NP group_NN and_CC the_DT aromatic_JJ benzimidazole_NN ._SENT Functional_JJ activity_NN of_IN lerisetron_NP |_SYM Whole_NP cell_NN patch-clamp_NN experiments_NNS were_VBD performed_VBN to_TO test_VB the_DT functional_JJ activity_NN of_IN lerisetron_NN ._SENT No_DT response_NN was_VBD observed_VBN when_WRB lerisetron_NN was_VBD applied_VBN alone_RB (_( data_NNS not_RB shown_VBN )_) ._SENT When_WRB co-applied_VBN with_IN 5-HT_JJ ,_, lerisetron_NN inhibited_VBD the_DT absolute_JJ magnitude_NN of_IN the_DT response_NN with_IN no_DT apparent_JJ alteration_NN of_IN the_DT response_NN profile_NN ._SENT The_DT combination_NN of_IN several_JJ identical_JJ inhibition_NN experiments_NNS produced_VBD a_DT Ki_NP value_NN of_IN 0.2_CD +-_NN 0.03_CD nM_NN for_IN lerisetron_NN inhibition_NN of_IN the_DT 5-HT_JJ induced_VBN response_NN ._SENT These_DT data_NNS correspond_VBP well_RB with_IN previously_RB reported_VBN data_NNS for_IN this_DT compound_NN and_CC verify_VB the_DT competitive_JJ antagonist_NN action_NN of_IN lerisetron_NN ._SENT Analogs_NNS of_IN lerisetron_NN have_VBP been_VBN shown_VBN to_TO inhibit_VB 5-HT3Rs_JJ in_IN a_DT similar_JJ manner_NN ._SENT Figure_NP 2_CD |_SYM Inhibition_NN of_IN 5-HT_JJ induced_VBN responses_NNS by_IN Lerisetron_NP ._SENT Inhibition_NN of_IN 5-HT_JJ induced_VBN responses_NNS by_IN Lerisetron_NP ._SENT tsA_NN 201_CD cells_NNS transfected_VBN with_IN 5-HT3ASR_NP cDNA_NN were_VBD clamped_VBN at_IN a_DT holding_NN potential_NN of_IN -60_CD mV_NN and_CC perfused_VBN with_IN 4_CD muM_NN 5-HT_NN (_( lower_JJR trace_NN )_) or_CC 4_CD muM_NN 5-HT_NN and_CC 0.3_CD nM_NN lerisetron_NN (_( upper_JJ trace_NN )_) ._SENT Lerisetron_NP reduced_VBD the_DT peak_NN 5-HT_JJ induced_VBN currents_NNS from_IN 2.0_CD nA_NN to_TO 1.0_CD nA_NN with_IN no_DT change_NN in_IN the_DT response_NN characteristics_NNS ._SENT An_DT IC50_NP value_NN was_VBD determined_VBN by_IN a_DT combination_NN of_IN similar_JJ experiments_NNS and_CC determined_VBN to_TO be_VB 0.4_CD +-_NN 0.03_CD nM_NN ._SENT Importance_NN of_IN the_DT N-benzyl_NP and_CC distal_JJ piperazine_NN nitrogen_NN to_TO binding_VBG of_IN lerisetron_NP |_SYM The_DT Ki_NP value_NN for_IN lerisetron_NN inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN to_TO wildtype_NN receptors_NNS was_VBD determined_VBN to_TO be_VB 0.8_CD +-_NN 0.19_CD nM_NN (_( Figure_NP and_CC Table_NP )_) ._SENT This_DT value_NN agrees_VBZ with_IN previously_RB published_VBN data_NNS for_IN this_DT compound_NN ._SENT The_DT Ki_NP values_NNS for_IN analogs_NNS 1_CD and_CC 2_CD under_IN identical_JJ conditions_NNS are_VBP 25_CD +-_NN 3.2_CD nM_NN and_CC 320_CD +-_NN 82_CD nM_NN respectively_RB (_( Figure_NP ,_, Table_NP )_) ._SENT The_DT observed_JJ change_NN in_IN Ki_NP represents_VBZ the_DT decreases_NNS in_IN binding_JJ energy_NN resulting_VBG from_IN removal_NN of_IN the_DT N-benzyl_NP group_NN (_( analog_NN 1_CD )_) and_CC the_DT distal_JJ piperazine_NN nitrogen_NN (_( analog_NN 2_CD )_) ._SENT Figure_NP 3_CD |_SYM Inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN to_TO mutant_NN and_CC wildtype_NN receptors_NNS by_IN lerisetron_NN ._SENT Inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN to_TO mutant_NN and_CC wildtype_NN receptors_NNS by_IN lerisetron_NN ._SENT Competition_NN binding_NN assays_NNS were_VBD performed_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Each_DT point_NN represents_VBZ a_DT mean_JJ +-_NN SE_NN of_IN n>4_JJ experiments_NNS ._SENT Ki_NP values_NNS calculated_VBN from_IN this_DT data_NNS and_CC the_DT relative_JJ magnitude_NN of_IN the_DT shift_NN in_IN Ki_NP compared_VBN to_TO wildtype_NN receptors_NNS are_VBP shown_VBN in_IN Table_NP ._SENT Y140A_NP produced_VBD no_DT significant_JJ change_NN in_IN Ki_NP values_NNS ._SENT W89F_NP ,_, W89Y_NP and_CC R91A_NP mutations_NNS produced_VBD moderate_JJ increases_NNS in_IN Ki_NP ._SENT Y142A_NP and_CC Y152A_NP mutations_NNS resulted_VBD in_IN increases_NNS in_IN Ki_NP of_IN 160_CD and_CC 190_CD fold_NN respectively_RB ._SENT Figure_NP 4_CD |_SYM Inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN to_TO wildtype_NN and_CC mutant_JJ receptors_NNS by_IN analog_JJ 1_CD and_CC analog_JJ 2_CD ._SENT Inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN to_TO wildtype_NN and_CC mutant_JJ receptors_NNS by_IN analog_JJ 1_CD and_CC analog_JJ 2_CD ._SENT Competition_NN binding_NN assays_NNS were_VBD performed_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Each_DT point_NN represents_VBZ a_DT mean_JJ +-_NN SE_NN of_IN n>_JJ 4_CD experiments_NNS ._SENT IC50_NP values_NNS were_VBD determined_VBN from_IN the_DT data_NNS and_CC a_DT Ki_NP value_NN calculated_VBD using_VBG the_DT Cheng-Prusoff_NP equation_NN ._SENT Ki_NP values_NNS for_IN inhibition_NN on_IN each_DT mutant_NN are_VBP shown_VBN in_IN Table_NP for_IN all_DT three_CD compounds_NNS ._SENT A._NP Wildtype_NP B._NP W89F_NP C._NP W89Y_NP D._NP R91A_NP E._NP Y142A_NP F._NP Y152A_NP Table_NP 1_CD |_SYM Summary_NN of_IN inhibition_NN data_NNS obtained_VBN for_IN lerisetron_NN ,_, analog_JJ 1_CD and_CC analog_JJ 2_CD on_IN mutant_NN and_CC wildtype_NN receptors_NNS ._SENT Ki_NP values_NNS were_VBD calculated_VBN from_IN IC50_JJ values_NNS as_IN previously_RB described_VBN ._SENT All_DT data_NN is_VBZ the_DT result_NN of_IN n_NN >_SYM 4_CD experiments_NNS and_CC is_VBZ expressed_VBN as_IN the_DT mean_JJ +-_NN SE_NN ._SENT The_DT relative_JJ change_NN in_IN Ki_NP was_VBD calculated_VBN as_IN the_DT Ki_NP (_( mutant_JJ )_) /_SYM Ki_NP (_( wildtype_NN )_) and_CC indicates_VBZ the_DT increase_NN in_IN Ki_NP relative_JJ to_TO wildtype_NN +-_NN SE_NN ._SENT *_SYM indicates_VBZ significant_JJ difference_NN in_IN fold_NN change_NN value_NN ._SENT Kd_NN values_NNS for_IN [_SYM 3H]granisetron_JJ binding_NN to_TO wt_NN and_CC mutant_JJ receptors_NNS were_VBD reproduced_VBN from_IN reference_NN 25_CD ._SENT Identification_NN of_IN amino_NN acids_NNS interacting_VBG with_IN Lerisetron_NP |_SYM In_IN order_NN to_TO determine_VB the_DT nature_NN of_IN the_DT amino_NN acids_NNS interacting_VBG with_IN the_DT distal_JJ amino_NN and_CC N-benzyl_NN groups_NNS of_IN lerisetron_NN ,_, we_PP constructed_VBD 5-HT3ASRs_JJ containing_VBG mutations_NNS at_IN W89_NP ,_, R91_NP ,_, Y140_NP ,_, Y142_NP and_CC Y152_NP ._SENT Figure_NN shows_VBZ inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN by_IN lerisetron_NN on_IN wildtype_NN and_CC mutant_JJ receptors_NNS ._SENT For_IN most_JJS amino_NN acids_NNS ,_, an_DT alanine_NN substitution_NN was_VBD constructed_VBN in_IN order_NN to_TO effectively_RB remove_VB any_DT amino_NN acid_NN interaction_NN with_IN the_DT ligand_NN ._SENT For_IN W89_NP ,_, an_DT alanine_NN substitution_NN has_VBZ been_VBN shown_VBN to_TO prevent_VB binding_JJ of_IN [_SYM 3H]granisetron_JJ ;_: therefore_RB a_DT less_RBR severe_JJ mutation_NN was_VBD constructed_VBN ._SENT The_DT W89F_NP mutation_NN produces_VBZ a_DT 18-fold_NN change_NN in_IN Kd_NP for_IN [_SYM 3H]-granisetron_JJ binding_NN (_( 18_CD +-_NN 2_CD nM_NN )_) and_CC the_DT W89Y_NP mutation_NN produces_VBZ a_DT 5.8-fold_NN change_NN in_IN Kd_NP (_( 5.7_CD +-_NN 0.7_CD nM_NN )_) ._SENT Mutation_NN of_IN amino_NN acid_NN R91_JJ to_TO alanine_NN produced_VBD a_DT 5-fold_NN change_NN in_IN Kd_NP for_IN [_SYM 3H]granisetron_JJ binding_NN (_( 4.9_CD +-_NN 0.7_CD nM_NN )_) ._SENT These_DT data_NNS agree_VBP well_RB with_IN previously_RB reported_VBN values_NNS ._SENT Alanine_NN mutations_NNS at_IN the_DT tyrosine_NN positions_NNS Y140_NP ,_, Y142_NP and_CC Y152_NP also_RB produced_VBD minor_JJ increases_NNS in_IN Kd_NP for_IN [_SYM 3H]granisetron_JJ binding_NN (_( 2.7_CD +-_NN 0.19_CD nM_NN ,_, 4.5_CD +-_NN 0.5_CD nM_NN and_CC 7.8_CD +-_NN 1.1_CD nM_NNS respectively_RB )_) ._SENT Only_JJ small_JJ changes_NNS in_IN Ki_NP for_IN lerisetron_NN were_VBD observed_VBN for_IN the_DT Y140A_NP mutation_NN while_IN the_DT Y142A_NP and_CC Y152A_NP mutations_NNS produced_VBD large_JJ increases_NNS in_IN the_DT Ki_NP (_( Table_NP and_CC Figure_NP )_) ._SENT For_IN W89F_NP and_CC W89Y_NP ,_, the_DT changes_NNS in_IN Ki_NP observed_VBD for_IN lerisetron_NN were_VBD much_RB smaller_JJR than_IN for_IN the_DT alanine_NN mutations_NNS at_IN Y142A_NP and_CC Y152A_NP ,_, as_RB would_MD be_VB expected_VBN for_IN the_DT less_RBR severe_JJ nature_NN of_IN these_DT mutations_NNS ._SENT The_DT changes_NNS were_VBD ,_, however_RB significant_JJ (_( p_NN <_SYM 0.001_CD in_IN both_DT cases_NNS )_) and_CC are_VBP similar_JJ to_TO the_DT changes_NNS in_IN Kd_NP reported_VBD for_IN [_SYM 3H]granisetron_JJ ._SENT The_DT increase_NN in_IN Ki_NP on_IN the_DT W89F_NP mutant_JJ receptor_NN was_VBD 4.8_CD +-_NN 0.56_CD fold_NN and_CC the_DT increase_NN in_IN Ki_NP on_IN the_DT W89Y_NP receptor_NN was_VBD 3.6_CD +-_NN 0.4_CD fold_NN ._SENT The_DT R91A_NP mutant_NN produced_VBD an_DT increase_NN in_IN Ki_NP of_IN 7.6_CD +-_NN 1.5_CD fold_NN as_IN compared_VBN to_TO the_DT wildtype_NN receptor_NN ._SENT These_DT data_NNS indicated_VBD potential_JJ interactions_NNS of_IN lerisetron_NN with_IN W89_NP ,_, R91_NP ,_, Y142_NP and_CC Y152_NP ._SENT Mutation_NN of_IN W89_NP |_SYM As_RB mentioned_VBN above_RB ,_, the_DT lack_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN to_TO W89A_NP mutant_JJ receptors_NNS necessitated_VBD the_DT use_NN of_IN W89F_NP and_CC W89Y_NP mutations_NNS to_TO analyze_VB functional_JJ group_NN interactions_NNS ._SENT The_DT effects_NNS of_IN these_DT mutations_NNS on_IN the_DT Ki_NP for_IN analogs_NNS 1_CD and_CC 2_CD are_VBP shown_VBN in_IN figure_NN ,_, and_CC Table_NP ._SENT Analog_NP 1_CD inhibited_VBN [_SYM 3H]-granisetron_JJ binding_NN to_TO W89F_NP receptors_NNS with_IN a_DT Ki_NP of_IN 170_CD +-_NN 54_CD nM_NN (_( 7_CD +-_NN 3.2_CD fold_NN increase_NN ,_, p_NN <_SYM 0.001_CD )_) and_CC W89Y_NP receptors_NNS with_IN a_DT Ki_NP of_IN 81_CD +-_NN 14_CD nM_NN (_( 3.2_CD +-_NN 0.6_CD fold_NN increase_NN ,_, p_NN <_SYM 0.001_CD )_) ._SENT This_DT reflects_VBZ a_DT significant_JJ increase_NN in_IN Ki_NP and_CC reflects_VBZ a_DT potential_JJ interaction_NN of_IN analog_JJ 1_CD with_IN W89_NP ._SENT The_DT strength_NN of_IN this_DT interaction_NN is_VBZ apparently_RB similar_JJ to_TO the_DT strength_NN of_IN the_DT interaction_NN with_IN [_SYM 3H]-granisetron_JJ and_CC lerisetron_NN since_IN the_DT magnitude_NN of_IN the_DT change_NN is_VBZ similar_JJ in_IN both_DT cases_NNS ._SENT Analog_NP 2_CD also_RB showed_VBD a_DT significant_JJ increase_NN in_IN Ki_NP as_IN a_DT result_NN of_IN the_DT W89F_NP and_CC W89Y_NP mutations_NNS ._SENT The_DT magnitude_NN of_IN the_DT change_NN for_IN W89F_NP (_( 5.1_CD +-_NN 1.3_CD fold_NN ,_, p_NN <_SYM 0.05_CD )_) was_VBD similar_JJ to_TO that_WDT observed_VBD for_IN lerisetron_NN and_CC analog_JJ 1_CD ._SENT The_DT W89Y_NP mutation_NN produced_VBD a_DT 6.8_CD +-_NN 1.6_CD fold_NN change_NN in_IN Ki_NP (_( p_NN <_SYM 0.05_CD )_) ._SENT Thus_RB ,_, all_DT three_CD compounds_NNS appear_VBP to_TO form_VB similar_JJ interactions_NNS with_IN W89_NP ._SENT Mutation_NN of_IN R91_NP |_SYM Mutation_NP of_IN R91_NP to_TO alanine_NN (_( R91A_NP )_) resulted_VBD in_IN a_DT significant_JJ ,_, but_CC small_JJ increase_NN in_IN Ki_NP for_IN lerisetron_NN of_IN 7.6_CD +-_NN 1.5_CD fold_NN (_( p_NN <_SYM 0.01_CD )_) ._SENT Figure_NN shows_VBZ the_DT inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN by_IN analogs_NNS 1_CD and_CC 2_CD at_IN R91A_NP mutant_JJ receptors_NNS ._SENT No_DT significant_JJ change_NN in_IN Ki_NP was_VBD observed_VBN on_IN these_DT receptors_NNS for_IN either_DT analog_NN 1_CD (_( 0.9_CD +-_NN 0.28_CD fold_NN )_) or_CC analog_NN 2_CD (_( 0.56_CD +-_NN 0.14_CD fold_NN )_) as_IN compared_VBN to_TO the_DT wildtype_NN receptor_NN ._SENT Mutation_NN of_IN Y142_NP |_SYM Mutation_NP of_IN Y142_NP to_TO alanine_NN produced_VBD one_CD of_IN the_DT largest_JJS observed_JJ changes_NNS in_IN Ki_NP for_IN lerisetron_NP (_( Figure_NP and_CC Table_NP )_) ._SENT The_DT Ki_NP obtained_VBD for_IN lerisetron_NN was_VBD 130_CD +-_NN 28_CD nM_NN ,_, reflecting_VBG a_DT change_NN of_IN 160_CD +-_NN 37_CD fold_NN compared_VBN to_TO wildtype_NN receptors_NNS ._SENT The_DT Ki_NP value_NN for_IN analog_JJ 1_CD ,_, in_IN contrast_NN ,_, increased_VBD only_RB 6.8_CD +-_NN 2.3_CD fold_NN (_( p_NN <_SYM 0.01_CD )_) as_IN a_DT result_NN of_IN this_DT mutation_NN (_( Figure_NP and_CC Table_NP )_) ._SENT The_DT Ki_NP for_IN analog_JJ 2_CD showed_VBD a_DT similar_JJ change_NN of_IN 17_CD +-_NN 0.77_CD fold_NN (_( p_NN <_SYM 0.01_CD )_) ._SENT While_IN these_DT Ki_NP values_NNS are_VBP significantly_RB different_JJ from_IN wildtype_NN values_NNS for_IN each_DT analog_NN ,_, the_DT lack_NN of_IN larger_JJR effects_NNS suggests_VBZ that_IN neither_DT analog_JJ 1_CD nor_CC analog_JJ 2_CD bind_NN as_IN strongly_RB as_IN lerisetron_NN to_TO Y142_NP ._SENT Mutation_NN of_IN Y152_NP |_SYM The_DT Y152A_NP mutation_NN showed_VBD the_DT most_JJS variability_NN in_IN its_PP$ effects_NNS on_IN Ki_NP values_NNS for_IN lerisetron_NN ,_, analog_JJ 1_CD and_CC analog_NN 2_CD (_( Figure_NP ,_, Figure_NP and_CC Table_NP )_) ._SENT Lerisetron_NP inhibited_VBD [_SYM 3H]-granisetron_JJ binding_NN with_IN a_DT Ki_NP value_NN of_IN 150_CD +-_NN 36_CD ;_: an_DT increase_NN of_IN 190_CD +-_NN 43_CD fold_NN compared_VBN to_TO wildtype_NN values_NNS ._SENT The_DT Ki_NP value_NN for_IN analog_JJ 1_CD increased_VBN from_IN 25_CD +-_NN 3.2_CD nM_NN (_( wildtype_NN )_) to_TO 2.5_CD +-_NN 0.40_CD muM_NN ._SENT This_DT change_NN of_IN 100_CD +-_NN 16_CD fold_NN is_VBZ slightly_RB smaller_JJR ,_, but_CC not_RB significantly_RB different_JJ from_IN the_DT relative_JJ change_NN observed_VBD for_IN lerisetron_NN ._SENT The_DT Ki_NP for_IN analog_JJ 2_CD increased_VBN from_IN 0.32_CD +-_NN 0.08_CD muM_NN on_IN wildtype_NN to_TO 13_CD +-_NN 4.2_CD muM_NN on_IN Y152A_NP mutant_JJ receptors_NNS (_( 40_CD +-_NN 12_CD fold_NN increase_NN )_) ._SENT The_DT increase_NN observed_VBD for_IN analog_JJ 2_CD was_VBD significantly_RB less_JJR than_IN that_DT observed_VBN for_IN both_DT lerisetron_NN and_CC analog_JJ 1_CD ._SENT The_DT smaller_JJR change_NN in_IN Ki_NP for_IN analog_JJ 2_CD suggests_VBZ that_DT analog_JJ 2_CD binds_NNS weakly_JJ to_TO Y152_NP while_IN lerisetron_NN and_CC analog_JJ 1_CD bind_NN more_JJR tightly_RB ._SENT The_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO ascertain_VB the_DT functional_JJ group_NN interactions_NNS of_IN lerisetron_NN with_IN specific_JJ amino_NN acids_NNS present_JJ in_IN the_DT 5-HT3R_NP binding_JJ site_NN ._SENT To_TO this_DT end_NN ,_, we_PP examined_VBD the_DT effects_NNS of_IN specific_JJ amino_NN acid_NN mutations_NNS on_IN the_DT binding_NN of_IN lerisetron_NN and_CC two_CD analogs_NNS ._SENT These_DT analogs_NNS ,_, shown_VBN in_IN Figure_NP ,_, are_VBP identical_JJ to_TO lerisetron_NN in_IN structure_NN ;_: however_RB ,_, each_DT analog_NN lacks_VBZ a_DT single_JJ functional_JJ group_NN found_VBN in_IN lerisetron_NN ._SENT By_IN comparing_VBG the_DT effects_NNS of_IN a_DT specific_JJ amino_NN acid_NN mutation_NN on_IN the_DT Ki_NP for_IN inhibition_NN of_IN [_SYM 3H]-granisetron_JJ binding_NN ,_, we_PP can_MD begin_VB to_TO identify_VB the_DT functional_JJ groups_NNS likely_JJ to_TO participate_VB in_IN that_DT interaction_NN ._SENT Five_CD different_JJ amino_NN acids_NNS were_VBD tested_VBN :_: W89_NP ,_, R91_NP ,_, Y140_NP ,_, Y142_NP and_CC Y152_NP ._SENT Each_DT of_IN these_DT amino_NN acids_NNS has_VBZ been_VBN shown_VBN in_IN previous_JJ studies_NNS to_TO alter_VB the_DT binding_NN of_IN 5-HT3R_NN ligands_NNS ._SENT A_DT summary_NN of_IN the_DT changes_NNS in_IN Ki_NP is_VBZ presented_VBN as_IN a_DT bar_NN chart_NN in_IN Figure_NP and_NP ._SENT Figure_NP 5_CD |_SYM Relative_JJ increases_NNS in_IN Ki_NP for_IN lerisetron_NN ,_, analog_JJ 1_CD and_CC analog_JJ 2_CD on_IN mutant_NN and_CC wildtype_NN receptors_NNS ._SENT Relative_JJ increases_NNS in_IN Ki_NP for_IN lerisetron_NN ,_, analog_JJ 1_CD and_CC analog_JJ 2_CD on_IN mutant_NN and_CC wildtype_NN receptors_NNS ._SENT The_DT relative_JJ change_NN in_IN Ki_NP was_VBD determined_VBN as_IN Ki_NP (mutant)/_NP Ki_NP (_( wildtype_NN )_) for_IN each_DT compound_NN ._SENT A._NP W89Y_NP ,_, W89F_NP ,_, R91A_NP B._NP Y140A_NP ,_, Y142A_NP ,_, Y152A_NP ._SENT Lerisetron_NP showed_VBD a_DT significant_JJ increase_NN in_IN Ki_NP for_IN all_DT mutants_NNS except_IN Y140A_NP ._SENT Increases_NNS in_IN Ki_NP were_VBD observed_VBN for_IN analog_JJ 1_CD and_CC 2_CD on_IN W89_NP and_CC Y152A_NP ._SENT While_IN lerisetron_NN binds_NNS to_TO wildtype_NN receptors_NNS with_IN high_JJ affinity_NN ,_, analog_JJ 1_CD binds_NNS with_IN lower_JJR affinity_NN (_( 31_CD fold_NN increase_NN in_IN Ki_NP compared_VBN to_TO lerisetron_NN )_) ._SENT Analog_NP 2_CD ,_, which_WDT lacks_VBZ the_DT terminal_JJ nitrogen_NN of_IN lerisetron_NN ,_, binds_NNS with_IN even_RB lower_JJR affinity_NN (_( a_DT 400-fold_JJ fold_NN increase_NN in_IN Ki_NP compared_VBN to_TO lerisetron_NN --_: Table_NP )_) ._SENT These_DT data_NNS demonstrate_VBP the_DT relative_JJ importance_NN of_IN the_DT N-benzyl_NP and_CC the_DT terminal_JJ nitrogen_NN moieties_NNS for_IN lerisetron_NN binding_NN ._SENT Cation-pi_NP interactions_NNS involving_VBG aromatic_JJ residues_NNS and_CC a_DT quaternary_JJ ammonium_NN have_VBP been_VBN demonstrated_VBN to_TO play_VB a_DT major_JJ role_NN in_IN binding_VBG of_IN nicotinic_JJ ligands_NNS to_TO nAchRs_NNS ._SENT Our_PP$ data_NNS support_VBP a_DT similar_JJ role_NN for_IN Y142_NP and_CC Y152_NP in_IN binding_VBG of_IN lerisetron_NN to_TO the_DT 5-HT3A_NP receptor_NN ._SENT Functional_JJ group_NN interactions_NNS of_IN W89_NP |_SYM The_DT W89F_NP mutation_NN produced_VBD a_DT significant_JJ increase_NN in_IN Ki_NP for_IN all_DT three_CD compounds_NNS ._SENT The_DT magnitude_NN of_IN the_DT change_NN was_VBD similar_JJ in_IN all_DT cases_NNS ._SENT In_IN addition_NN ,_, the_DT increase_NN in_IN Ki_NP was_VBD identical_JJ to_TO the_DT increase_NN in_IN Kd_NP that_WDT has_VBZ been_VBN observed_VBN for_IN [_SYM 3H]granisetron_JJ binding_NN on_IN this_DT mutant_NN ._SENT Alterations_NNS in_IN Ki_NP resulting_VBG from_IN the_DT W89Y_NP mutation_NN were_VBD slightly_RB less_JJR ,_, however_RB the_DT change_NN was_VBD again_RB the_DT same_JJ for_IN lerisetron_NN ,_, analog_JJ 1_CD and_CC analog_JJ 2_CD ._SENT These_DT data_NNS suggest_VBP that_IN all_DT three_CD compounds_NNS form_VBP binding_JJ site_NN interactions_NNS with_IN W89_NP ._SENT The_DT interaction_NN between_IN lerisetron_NP and_CC W89_NP is_VBZ unlikely_JJ to_TO be_VB via_IN the_DT N-benzyl_NP functional_JJ group_NN since_IN the_DT Ki_NP for_IN analog_JJ 1_CD was_VBD also_RB altered_VBN by_IN this_DT mutation_NN ._SENT The_DT same_JJ argument_NN can_MD be_VB made_VBN for_IN the_DT distal_JJ piperazine_NN nitrogen_NN since_IN the_DT Ki_NP for_IN analog_JJ 2_CD also_RB increased_VBN ._SENT The_DT portion_NN of_IN the_DT molecule_NN common_JJ to_TO all_DT three_CD compounds_NNS ,_, the_DT aromatic_JJ benzimidazole_NN ,_, is_VBZ thus_RB the_DT most_RBS likely_JJ point_NN of_IN interaction_NN for_IN W89_NP ._SENT Functional_JJ group_NN interactions_NNS of_IN R91_NP |_SYM The_DT R91A_NP mutation_NN increased_VBD the_DT Ki_NP value_NN for_IN lerisetron_NN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN by_IN 7.6_CD fold_NN ._SENT This_DT is_VBZ a_DT moderately_RB small_JJ change_NN for_IN an_DT alanine_NN mutation_NN ,_, particularly_RB considering_VBG that_IN the_DT smallest_JJS change_NN in_IN Ki_NP for_IN removal_NN of_IN a_DT functional_JJ group_NN on_IN lerisetron_NN (_( the_DT N-benzyl_NP group_NN )_) was_VBD 31_CD fold_NN ._SENT It_PP is_VBZ therefore_RB likely_JJ that_IN this_DT interaction_NN is_VBZ either_RB extremely_RB weak_JJ or_CC the_DT change_NN in_IN Ki_NP is_VBZ the_DT result_NN of_IN a_DT structural_JJ change_NN in_IN the_DT binding_JJ site_NN ._SENT Previous_JJ studies_NNS concluded_VBD that_IN R91_NP was_VBD an_DT important_JJ interaction_NN for_IN the_DT 5-HT3R_NP agonist_NN 5-hydroxytryptamine_NN (_( 5-HT_JJ )_) ,_, since_IN the_DT Ki_NP for_IN 5-HT_JJ inhibition_NN increased_VBN over_IN 3000_CD fold_NN as_IN a_DT result_NN of_IN the_DT R91A_NP mutation_NN ._SENT A_DT change_NN in_IN Kd_NP for_IN [_SYM 3H]granisetron_JJ binding_NN to_TO R91A_NP was_VBD also_RB observed_VBN ._SENT In_IN order_NN to_TO determine_VB whether_IN the_DT N-benzyl_NP or_CC distal_JJ piperazine_NN nitrogen_NN of_IN lerisetron_NN was_VBD involved_VBN in_IN an_DT interaction_NN with_IN R91_NP ,_, we_PP tested_VBD both_DT analog_JJ 1_CD and_CC 2_CD on_IN R91A_NP mutant_JJ receptors_NNS ._SENT No_DT change_NN in_IN Ki_NP was_VBD observed_VBN for_IN either_DT compound_NN ._SENT This_DT result_NN makes_VBZ it_PP much_RB more_RBR difficult_JJ to_TO assign_VB the_DT correct_JJ functional_JJ group_NN to_TO this_DT amino_NN acid_NN since_IN it_PP suggests_VBZ that_IN one_PP or_CC both_DT of_IN the_DT compounds_NNS is_VBZ no_RB longer_RBR binding_VBG the_DT receptor_NN in_IN precisely_RB the_DT same_JJ manner_NN as_IN lerisetron_NN ._SENT Considering_VBG the_DT small_JJ change_NN observed_VBD for_IN lerisetron_NN binding_VBG as_IN a_DT result_NN of_IN this_DT mutation_NN ,_, even_RB a_DT slight_JJ reorientation_NN of_IN the_DT molecule_NN in_IN the_DT binding_JJ site_NN could_MD result_VB in_IN the_DT loss_NN of_IN this_DT interaction_NN ._SENT Functional_JJ group_NN interactions_NNS of_IN Y142_NP |_SYM The_DT Ki_NP values_NNS for_IN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN by_IN analogs_NNS 1_CD and_CC 2_CD were_VBD altered_VBN only_RB slightly_RB by_IN the_DT Y142A_NP mutation_NN ._SENT The_DT magnitude_NN of_IN the_DT increase_NN in_IN Ki_NP for_IN lerisetron_NN ,_, however_RB ,_, was_VBD considerably_RB larger_JJR (_( 160_CD fold_NN )_) and_CC is_VBZ indicative_JJ of_IN an_DT important_JJ interaction_NN of_IN the_DT compound_NN with_IN Y142_NP ._SENT The_DT lack_NN of_IN a_DT large_JJ change_NN in_IN Ki_NP for_IN both_DT analogs_NNS makes_VBZ it_PP difficult_JJ to_TO interpret_VB this_DT data_NNS since_IN one_CD or_CC both_DT of_IN the_DT compounds_NNS appears_VBZ to_TO be_VB interacting_VBG differently_RB with_IN the_DT binding_JJ site_NN than_IN lerisetron_NN ._SENT Analogs_NNS 1_CD and_CC 2_CD differ_VBP from_IN each_DT other_JJ both_CC in_IN the_DT functional_JJ groups_NNS contained_VBN in_IN the_DT molecule_NN and_CC their_PP$ structural_JJ similarity_NN to_TO lerisetron_NN ._SENT Analog_NP 2_CD is_VBZ most_RBS similar_JJ in_IN overall_JJ structure_NN ._SENT The_DT substitution_NN of_IN oxygen_NN for_IN the_DT distal_JJ amino_NN nitrogen_NN alters_VBZ the_DT potential_JJ interactions_NNS formed_VBN at_IN this_DT position_NN ,_, but_CC is_VBZ likely_JJ to_TO have_VB a_DT small_JJ effect_NN on_IN the_DT overall_JJ size_NN and_CC shape_NN of_IN the_DT molecule_NN ._SENT Analog_NP 1_CD is_VBZ far_RB less_RBR similar_JJ to_TO lerisetron_NN and_CC more_RBR similar_JJ to_TO the_DT 5-HT3R_NP antagonist_NN granisetron_NN ._SENT Previous_JJ studies_NNS have_VBP shown_VBN that_IN the_DT binding_NN of_IN granisetron_NN is_VBZ not_RB affected_VBN by_IN the_DT Y142A_NP mutation_NN ._SENT Analog_NP 1_CD may_MD bind_VB more_RBR similar_JJ to_TO granisetron_NN than_IN lerisetron_NN and_CC thus_RB would_MD be_VB unaffected_JJ by_IN mutations_NNS at_IN Y142_NP ._SENT This_DT is_VBZ less_RBR likely_JJ to_TO be_VB the_DT case_NN with_IN analog_JJ 2_CD ._SENT The_DT strength_NN of_IN the_DT putative_JJ interaction_NN at_IN Y142_NP can_MD be_VB identified_VBN by_IN examining_VBG the_DT change_NN in_IN binding_VBG of_IN lerisetron_NN as_IN a_DT result_NN of_IN the_DT Y142A_NP mutation_NN ._SENT The_DT Y142A_NP mutation_NN produced_VBD a_DT 160_CD fold_NN change_NN in_IN Ki_NP ._SENT This_DT change_NN reflects_VBZ the_DT binding_JJ energy_NN lost_VBN as_IN a_DT result_NN of_IN the_DT alanine_NN substitution_NN ._SENT The_DT observed_JJ change_NN in_IN Ki_NP on_IN wt_NN receptors_NNS is_VBZ much_RB larger_JJR than_IN that_DT observed_VBN for_IN removal_NN of_IN the_DT N-benzyl_NP group_NN (_( 31_CD fold_NN )_) ,_, but_CC is_VBZ similar_JJ to_TO that_WDT observed_VBD for_IN substitution_NN of_IN the_DT distal_JJ amino_NN nitrogen_NN in_IN analog_NN 2_CD (_( 400_CD fold_NN )_) ._SENT Taken_VBN together_RB with_IN the_DT close_JJ structural_JJ similarity_NN of_IN analog_NN 2_CD to_TO lerisetron_NN ,_, it_PP can_MD be_VB concluded_VBN that_DT comparison_NN of_IN analog_JJ 2_CD and_CC lerisetron_NN should_MD provide_VB the_DT best_JJS means_NNS of_IN identifying_VBG the_DT interaction_NN at_IN Y142_NP ._SENT No_DT change_NN in_IN Ki_NP was_VBD observed_VBN for_IN analog_JJ 2_CD as_IN a_DT result_NN of_IN the_DT Y142A_NP mutation_NN indicating_VBG a_DT lack_NN of_IN any_DT significant_JJ interaction_NN of_IN this_DT compound_NN with_IN Y142_NP ._SENT These_DT data_NNS support_VBP our_PP$ hypothesis_NN that_IN Y142_NP interacts_VBZ with_IN the_DT distal_JJ piperazine_NN nitrogen_NN of_IN lerisetron_NN ._SENT A_DT second_JJ amino_NN acid_NN may_MD also_RB be_VB involved_VBN since_IN the_DT change_NN in_IN Ki_NP for_IN lerisetron_NN binding_VBG as_IN a_DT result_NN of_IN the_DT Y142A_NP mutation_NN was_VBD smaller_JJR than_IN the_DT change_NN produced_VBN by_IN substitution_NN of_IN the_DT piperazine_NN nitrogen_NN ._SENT As_RB described_VBN below_RB ,_, one_CD candidate_NN for_IN this_DT second_JJ amino_NN acid_NN is_VBZ Y152_JJ ._SENT Functional_JJ group_NN interactions_NNS of_IN Y152_NP |_SYM The_DT Y152A_NP mutation_NN produced_VBD increases_NNS in_IN Ki_NP for_IN all_DT three_CD compounds_NNS although_IN the_DT magnitude_NN of_IN the_DT change_NN differed_VBD ._SENT The_DT increases_NNS in_IN the_DT Ki_NP values_NNS were_VBD 190_CD fold_NN for_IN lerisetron_NN ,_, 98_CD fold_NN for_IN analog_JJ 1_CD and_CC only_RB 40_CD fold_NN for_IN analog_JJ 2_CD ._SENT Thus_RB ,_, analog_NN 1_CD retains_VBZ much_RB of_IN its_PP$ ability_NN to_TO interact_VB with_IN Y152_NP despite_IN the_DT absence_NN of_IN the_DT N-benzyl_NP group_NN ,_, while_IN analog_NN 2_CD interacts_VBZ more_RBR weakly_JJ with_IN this_DT amino_NN acid_NN ._SENT Since_IN the_DT Ki_NP for_IN analog_JJ 1_CD is_VBZ increased_VBN by_IN the_DT Y152A_NP mutation_NN ,_, it_PP is_VBZ unlikely_JJ that_IN the_DT N-benzyl_NP group_NN interacts_VBZ with_IN Y152_NP ._SENT The_DT small_JJ change_NN in_IN Ki_NP for_IN analog_JJ 2_CD supports_NNS a_DT partial_JJ interaction_NN of_IN Y152_NP with_IN the_DT distal_JJ piperazine_NN nitrogen_NN although_IN some_DT interaction_NN with_IN another_DT group_NN is_VBZ also_RB apparent_JJ ._SENT This_DT other_JJ group_NN would_MD be_VB expected_VBN to_TO be_VB in_IN close_JJ proximity_NN to_TO the_DT distal_JJ nitrogen_NN ._SENT The_DT most_RBS likely_JJ candidate_NN is_VBZ the_DT other_JJ nitrogen_NN of_IN the_DT piperazine_NN ring_NN ._SENT Thus_RB Y152A_NP may_MD form_VB a_DT partial_JJ interaction_NN with_IN both_DT piperazine_NN nitrogens_NNS ._SENT Figure_NN shows_VBZ a_DT hypothetical_JJ model_NN of_IN the_DT lerisetron-binding_JJ site_NN supported_VBN by_IN our_PP$ observations_NNS ._SENT The_DT model_NN illustrates_VBZ the_DT secondary_JJ structure_NN of_IN the_DT region_NN of_IN the_DT receptor_NN from_IN Y140_NP --_: Y152_NP in_IN a_DT loop_NN configuration_NN ._SENT This_DT structure_NN is_VBZ supported_VBN by_IN site-directed_JJ mutagenesis_NN data_NNS as_RB well_RB as_IN structural_JJ predictions_NNS obtained_VBN from_IN other_JJ LGIC_JJ receptors_NNS ._SENT The_DT recent_JJ determination_NN of_IN the_DT structure_NN of_IN a_DT nicotinic_JJ acetylcholine_NN binding_VBG protein_NN that_WDT shares_VBZ significant_JJ homology_NN with_IN the_DT LGIC_JJ family_NN also_RB supports_VBZ a_DT loop_NN structure_NN in_IN this_DT part_NN of_IN the_DT protein_NN ._SENT The_DT region_NN from_IN W89_NP through_IN Y93_NP is_VBZ shown_VBN as_IN a_DT beta-sheet_NN as_RB has_VBZ been_VBN hypothesized_VBN based_VBN on_IN site-directed_JJ mutagenesis_NN studies_NNS of_IN this_DT strand_NN of_IN the_DT 5-HT3R_NN ._SENT Our_PP$ data_NNS indicate_VBP the_DT functional_JJ groups_NNS of_IN lerisetron_NN that_WDT may_MD interact_VB with_IN W89_NP ,_, R91_NP ,_, Y142_NP and_CC Y152_NP ._SENT Figure_NP 6_CD |_SYM Model_NP of_IN the_DT 5-HT3R_NP binding_JJ site_NN ._SENT Model_NN of_IN the_DT 5-HT3R_NP binding_JJ site_NN ._SENT The_DT model_NN illustrates_VBZ the_DT major_JJ points_NNS discussed_VBN in_IN the_DT text_NN ._SENT Lerisetron_NP is_VBZ shown_VBN spanning_VBG the_DT region_NN between_IN the_DT D_NP and_CC E_NP loops_NNS of_IN the_DT receptor_NN ._SENT Both_DT loops_NNS are_VBP illustrated_VBN as_IN beta-sheets_NNS as_IN described_VBN ._SENT The_DT side_NN chains_NNS are_VBP presumed_VBN to_TO point_VB in_RP or_CC out_RP of_IN the_DT page_NN depending_VBG on_IN their_PP$ position_NN ._SENT W89_NP ,_, R91_NP ,_, Y140_NP ,_, Y142_NP and_CC Y152_NP all_RB presumably_RB extend_VB into_IN the_DT binding_JJ site_NN ._SENT The_DT terminal_JJ piperazine_NN nitrogen_NN is_VBZ shown_VBN interacting_VBG primarily_RB with_IN Y142_NP ,_, but_CC is_VBZ also_RB capable_JJ of_IN forming_VBG an_DT interaction_NN with_IN Y152_NP ._SENT Y152_NP may_MD also_RB form_VB an_DT interaction_NN with_IN the_DT second_JJ piperazine_NN nitrogen_NN ._SENT W89_NP is_VBZ illustrated_VBN as_IN forming_VBG an_DT aromatic_JJ interaction_NN with_IN the_DT benzimidazole_NN ._SENT While_IN R91_NP is_VBZ shown_VBN in_IN close_JJ contact_NN to_TO the_DT N-benzyl_NP group_NN ,_, the_DT data_NNS support_VBP only_RB a_DT weak_JJ interaction_NN at_IN this_DT point_NN ._SENT W89_NP is_VBZ shown_VBN interacting_VBG with_IN the_DT aromatic_JJ benzimidazole_NN group_NN of_IN lerisetron_NN although_IN the_DT precise_JJ position_NN of_IN W89_NP relative_JJ to_TO this_DT group_NN is_VBZ not_RB known_VBN ._SENT The_DT W89_NP interaction_NN with_IN this_DT group_NN is_VBZ supported_VBN by_IN the_DT observed_JJ increase_NN in_IN Ki_NP for_IN lerisetron_NN ,_, analog_JJ 1_CD and_CC analog_JJ 2_CD ._SENT Since_IN the_DT benzimidazole_NN group_NN is_VBZ common_JJ to_TO all_DT three_CD compounds_NNS it_PP is_VBZ the_DT most_RBS likely_JJ point_NN of_IN interaction_NN ._SENT W89_NP also_RB represents_VBZ a_DT common_JJ interaction_NN in_IN the_DT binding_JJ site_NN for_IN both_DT lerisetron_NN and_CC [_SYM 3H]granisetron_JJ ._SENT Y142_NP is_VBZ shown_VBN interacting_VBG with_IN the_DT distal_JJ piperazine_NN nitrogen_NN possibly_RB through_IN a_DT cation-pi_NN interaction_NN ._SENT This_DT orientation_NN of_IN an_DT amino_NN group_NN interacting_VBG with_IN an_DT aromatic_JJ amino_NN acid_NN in_IN a_DT cation-pi_NN interaction_NN has_VBZ been_VBN shown_VBN for_IN the_DT nicotinic_JJ acetylcholine_NN receptor_NN and_CC has_VBZ been_VBN hypothesized_VBN for_IN many_JJ LGIC_JJ receptors_NNS [_SYM -_: ,_, ]_SYM ._SENT This_DT conclusion_NN is_VBZ based_VBN on_IN both_CC the_DT magnitude_NN of_IN the_DT change_NN observed_VBD on_IN the_DT wild_JJ type_NN receptor_NN for_IN removal_NN of_IN the_DT amino_NN group_NN (_( 400_CD fold_NN )_) compared_VBN to_TO the_DT effect_NN of_IN the_DT Y142A_NP mutation_NN on_IN lerisetron_NN binding_NN (_( 160_CD fold_NN )_) and_CC the_DT lack_NN of_IN any_DT major_JJ change_NN in_IN Ki_NP for_IN analog_JJ 2_CD as_IN a_DT result_NN of_IN this_DT mutation_NN ._SENT Our_PP$ data_NN does_VBZ not_RB support_VB an_DT interaction_NN of_IN this_DT amino_NN acid_NN with_IN either_CC the_DT N-benzyl_NN or_CC benzimidazole_NN portions_NNS of_IN lerisetron_NN ._SENT Y152_NP is_VBZ shown_VBN positioned_VBN between_IN the_DT two_CD piperazine_NN nitrogens_NNS ._SENT This_DT conclusion_NN is_VBZ supported_VBN by_IN the_DT smaller_JJR increase_NN in_IN Ki_NP for_IN analog_NN 2_CD (_( 40_CD fold_NN )_) compared_VBN to_TO that_WDT observed_VBD for_IN lerisetron_NN (_( 190_CD fold_NN )_) ._SENT These_DT results_NNS suggest_VBP a_DT partial_JJ interaction_NN of_IN Y152_NP with_IN the_DT distal_JJ piperazine_NN nitrogen_NN ._SENT Since_IN some_DT change_NN was_VBD observed_VBN ,_, a_DT second_JJ interaction_NN is_VBZ also_RB likely_JJ ._SENT The_DT functional_JJ group_NN in_IN closest_JJS proximity_NN to_TO the_DT distal_JJ piperazine_NN nitrogen_NN is_VBZ the_DT other_JJ nitrogen_NN on_IN the_DT piperazine_NN ring_NN ._SENT Another_DT possibility_NN would_MD be_VB the_DT N-benzyl_NP interaction_NN ,_, however_RB ,_, since_IN the_DT Y152A_NP mutation_NN also_RB produced_VBD a_DT large_JJ increase_NN in_IN Ki_NP for_IN analog_JJ 2_CD ,_, this_DT conclusion_NN is_VBZ not_RB supported_VBN by_IN our_PP$ data_NNS ._SENT R91_NP is_VBZ shown_VBN as_IN interacting_VBG with_IN the_DT N-benzyl_NP group_NN ._SENT This_DT is_VBZ a_DT difficult_JJ conclusion_NN to_TO make_VB considering_VBG the_DT small_JJ effect_NN of_IN the_DT R91A_NP mutation_NN on_IN lerisetron_NN binding_NN ._SENT The_DT interaction_NN is_VBZ included_VBN in_IN the_DT model_NN based_VBN on_IN structural_JJ information_NN obtained_VBN from_IN the_DT crystal_NN structure_NN of_IN AChBP_NP ._SENT The_DT region_NN of_IN this_DT protein_NN homologous_JJ to_TO loop_VB E_NN and_CC loop_NN D_NN of_IN the_DT 5-HT3A_NP receptor_NN suggests_VBZ a_DT loop_NN structure_NN from_IN Y140_NP to_TO Y152_NP and_CC a_DT 3-residue_JJ turn_NN containing_VBG a_DT glycine_NN at_IN position_NN 147_CD and_CC the_DT beta-strand_NN from_IN W89_NP through_IN Y93_NP oriented_VBN as_IN shown_VBN in_IN Figure_NP ._SENT The_DT orientation_NN of_IN lerisetron_NN between_IN W89_NP and_CC Y142A_NP as_IN shown_VBN would_MD enable_VB the_DT N-benzyl_NP group_NN to_TO be_VB positioned_VBN in_IN close_JJ proximity_NN to_TO R91_NP ._SENT If_IN this_DT is_VBZ the_DT case_NN ,_, then_RB a_DT small_JJ alteration_NN in_IN position_NN of_IN analog_JJ 1_CD or_CC 2_CD in_IN the_DT binding_JJ site_NN could_MD result_VB in_IN the_DT loss_NN of_IN this_DT presumably_RB weak_JJ interaction_NN ._SENT The_DT apparent_JJ alterations_NNS in_IN the_DT binding_JJ site_NN location_NN of_IN analog_JJ 1_CD would_MD be_VB consistent_JJ with_IN this_DT hypothesis_NN ._SENT An_DT alternate_JJ hypothesis_NN would_MD place_VB the_DT N-benzyl_NP group_NN in_IN a_DT different_JJ position_NN ,_, interacting_VBG with_IN another_DT amino_NN acid_NN ;_: either_CC solely_RB or_CC in_IN concert_NN with_IN R91_NP ._SENT Our_PP$ data_NNS support_VBP a_DT binding_JJ site_NN for_IN lerisetron_NN on_IN the_DT 5-HT3R_NN that_WDT spans_VBZ the_DT D_NP and_CC E_NP loop_NN regions_NNS ._SENT Table_NN shows_VBZ the_DT sequence_NN alignment_NN for_IN the_DT 5-HT3R_NP ,_, the_DT alpha7_JJ receptor_NN and_CC the_DT AChBP_NP for_IN these_DT loops_NNS ._SENT Sequence_NN alignment_NN of_IN mouse_NN 5-HT3_JJ AR_NN ,_, alpha7_JJ nAchR_NN and_CC AChBP_JJ result_NN in_IN alignment_NN of_IN the_DT proposed_VBN D_NN and_CC E_NN loop_NN of_IN the_DT 5-HT3_JJ AR_NN with_IN corresponding_JJ regions_NNS of_IN the_DT alpha7_JJ nAchR_NN and_CC AChBP_NP ._SENT The_DT amino_NN acids_NNS W89_NP ,_, R91_NP Y140_NP ,_, Y142_NP and_CC Y152_NP of_IN the_DT 5HT3_NN A_DT R_NN can_MD be_VB aligned_VBN with_IN W53_NP ,_, Q55_NP ,_, L102_NP ,_, R104_NP ,_, and_CC M114_NP of_IN the_DT AChBP_NP ._SENT These_DT amino_NN acids_NNS form_VBP a_DT cluster_NN in_IN the_DT proposed_VBN acetylcholine_NN binding_VBG domain_NN of_IN AChBP_NP similar_JJ to_TO that_DT proposed_VBN in_IN our_PP$ model_NN ._SENT Both_DT loops_NNS have_VBP been_VBN identified_VBN on_IN the_DT complementary_JJ face_NN of_IN the_DT binding_JJ site_NN of_IN the_DT nAChR_NN ._SENT It_PP is_VBZ unknown_JJ if_IN lerisetron_NN utilizes_VBZ amino_NN acids_NNS on_IN the_DT principal_JJ face_NN although_IN none_NN have_VBP been_VBN identified_VBN ._SENT The_DT model_NN for_IN lerisetron_NN binding_NN will_MD be_VB further_RBR refined_VBN as_IN its_PP$ interactions_NNS with_IN other_JJ binding_JJ site_NN amino_NN acids_NNS are_VBP investigated_VBN ._SENT Of_IN particular_JJ interest_NN would_MD be_VB potential_JJ interactions_NNS of_IN the_DT N-benzyl_NP group_NN that_WDT would_MD account_VB for_IN the_DT decrease_NN in_IN binding_JJ affinity_NN of_IN analog_JJ 2_CD ._SENT Additional_JJ information_NN gained_VBD from_IN comparison_NN of_IN our_PP$ model_NN with_IN the_DT recent_JJ crystal_NN structure_NN of_IN the_DT AChBP_NP demonstrates_VBZ that_IN lerisetron_NN can_MD be_VB roughly_RB '_POS fit_NN '_'' into_IN the_DT binding_JJ site_NN such_JJ that_IN all_PDT the_DT residues_NNS line_NN up_RB as_RB shown_VBN in_IN our_PP$ model_NN ._SENT While_IN this_DT is_VBZ not_RB direct_JJ evidence_NN that_IN the_DT model_NN is_VBZ correct_JJ ,_, subsequent_JJ molecular_JJ modeling_NN of_IN the_DT data_NNS presented_VBN in_IN this_DT paper_NN may_MD provide_VB further_JJR support_NN for_IN our_PP$ hypothesis_NN ._SENT Our_PP$ current_JJ model_NN provides_VBZ an_DT initial_JJ working_NN hypothesis_NN that_WDT can_MD form_VB the_DT basis_NN of_IN further_JJR investigation_NN ._SENT Also_RB ,_, while_IN it_PP is_VBZ unclear_JJ whether_IN the_DT information_NN obtained_VBN in_IN this_DT study_NN can_MD be_VB extended_VBN to_TO other_JJ 5-HT3R_NN ligands_NNS ,_, a_DT similar_JJ approach_NN would_MD be_VB useful_JJ in_IN identifying_VBG functional_JJ group_NN interactions_NNS for_IN mCPBG_NN ,_, 5-HT_JJ ,_, dtC_NN and_CC granisetron_NN ._SENT Table_NP 2_CD |_SYM Sequence_NN alignment_NN of_IN the_DT mouse_NN 5-HT3R_NN with_IN the_DT mouse_NN nicotinic_JJ alpha7_JJ receptor_NN and_CC the_DT AChBP_NP ._SENT Two_CD sequences_NNS are_VBP shown_VBN ._SENT The_DT top_JJ sequence_NN is_VBZ the_DT putative_JJ D_NP loop_NN containing_VBG W89_NP and_CC R91_NP (_( homologous_JJ to_TO W53_NP and_CC Q55_NP of_IN the_DT AChBP_NP )_) ._SENT The_DT lower_JJR sequence_NN shows_VBZ the_DT putative_JJ E_NN loop_NN and_CC contains_VBZ Y140_NP ,_, Y142_NP and_CC Y152_NP (_( homologous_JJ to_TO L102_NP ,_, R104_NP and_CC M114_NP of_IN the_DT AChBP_NP )_) ._SENT Mutagenesis_NN |_SYM Wild_NP type_NN 5-HT3AS_NP mouse_NN receptor_NN cDNA_NN was_VBD derived_VBN from_IN N1E-115_NP neuroblastoma_NN cells_NNS as_IN previously_RB described_VBN ._SENT Mutant_JJ receptors_NNS were_VBD constructed_VBN using_VBG polymerase_NN chain_NN reaction_NN (_( Quick_RB change_VB mutagenesis_NN kit_NN ,_, Promega_NP )_) ._SENT All_DT mutations_NNS were_VBD confirmed_VBN by_IN DNA_NP sequencing_NP ._SENT Cell_NN culture_NN methods_NNS and_CC transfections_NNS |_SYM tsA201_JJ cells_NNS (_( a_DT derivative_NN of_IN the_DT HEK293_NP cell_NN line_NN )_) were_VBD grown_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagles_NP medium_NN (_( D-MEM_NP )_) containing_VBG 10_CD %_NN FBS_NP and_CC 100-units/ml_JJ penicillin/streptomycin_NN ._SENT Cultures_NNS were_VBD maintained_VBN in_IN humidified_VBN atmosphere_NN of_IN 5_CD %_NN CO2_NN at_IN 37C_JJ ._SENT For_IN binding_JJ studies_NNS ,_, tsA201_NN cells_NNS were_VBD plated_VBN at_IN a_DT density_NN of_IN 5_CD x_SYM 106_CD cells/75_NN cm2_NN and_CC grown_VBN for_IN 9_CD hours_NNS prior_RB to_TO transfection_NN ._SENT Cells_NNS were_VBD transfected_VBN with_IN 10_CD mug_NN murine_JJ 5-HT3ASR_NP cDNA_NN using_VBG calcium_NN phosphate_NN co-precipitation_NN (_( New_NP Life_NP Technologies_NPS ,_, NY_NP )_) ,_, then_RB incubated_VBD 36_CD hours_NNS prior_RB to_TO harvesting_NN ._SENT For_IN whole_JJ cell_NN patch_NN clamp_NN experiments_NNS ,_, tsA201_NN cells_NNS were_VBD plated_VBN at_IN a_DT density_NN of_IN 0.25_CD x_SYM 106_CD cells/27_JJ cm2_JJ dish_NN and_CC grown_VBN 12_CD hours_NNS prior_RB to_TO transfection_NN ._SENT Cells_NNS were_VBD washed_VBN with_IN fresh_JJ culture_NN medium_NN then_RB transfected_JJ with_IN 10_CD mug_NN 5-HT3ASR_NN cDNA_NN using_VBG Qiagen_NP Superfect_NP transfection_NN reagent_NN (_( Qiagen_NP ,_, CA_NP )_) ._SENT Transfected_JJ cells_NNS were_VBD incubated_VBN with_IN this_DT mixture_NN for_IN 2.5_CD hours_NNS ,_, then_RB divided_VBN into_IN 35_CD mm_NN culture_NN dishes_NNS at_IN a_DT density_NN of_IN approximately_RB 5_CD x_SYM 104_CD cells/dish_JJ and_CC incubated_VBN for_IN 24_CD hours_NNS at_IN 37C_JJ before_IN recording_NN ._SENT Radioligand_NP Binding_NP Assay_NP |_SYM Transfected_JJ cells_NNS were_VBD scraped_VBN from_IN the_DT dishes_NNS ,_, washed_VBN twice_RB with_IN Dulbecco_NP 's_POS PBS_NP (_( New_NP Life_NP Technologies_NPS ,_, NY_NP )_) ,_, then_RB resuspended_JJ in_IN 1.0_CD ml_NN PBS/100_JJ mm_NN dish_NN ._SENT Cells_NNS were_VBD either_RB used_VBN fresh_JJ or_CC frozen_VBN at_IN this_DT step_NN until_IN needed_VBN ._SENT Immediately_RB prior_RB to_TO use_VB ,_, cells_NNS were_VBD homogenized_VBN in_IN PBS_NP using_VBG a_DT glass_NN tissue_NN homogenizer_NN then_RB centrifuged_VBN at_IN 35_CD 000_CD x_SYM g_NN for_IN 30_CD minutes_NNS in_IN a_DT Beckman_NP JA20_NP rotor_NN ._SENT Membranes_NNS were_VBD washed_VBN once_RB more_RBR with_IN PBS_NP then_RB resuspended_VBD in_IN 1_CD ml_NN PBS/100_JJ mm_NN dish_NN ._SENT Protein_NN content_NN was_VBD determined_VBN using_VBG a_DT Lowry_NP assay_NN (_( Sigma_NP ._SENT Diagnostics_NNS ,_, St._NP Louis_NP ,_, MO_NP )_) ._SENT Binding_JJ assays_NNS were_VBD performed_VBN in_IN PBS_NP ._SENT For_IN Kd_NN determinations_NNS ,_, 100_CD mul_NN of_IN homogenate_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 1_CD hour_NN with_IN varying_VBG concentrations_NNS of_IN [_SYM 3H_NP ]_SYM granisetron_NN (_( NEN_NP ,_, MA_NP )_) ._SENT Specific_JJ binding_NN of_IN [_SYM 3H_NP ]_SYM granisetron_NN was_VBD determined_VBN as_IN the_DT bound_NN [_SYM 3H_NP ]_SYM granisetron_NN not_RB displaced_VBN by_IN a_DT saturating_VBG concentration_NN of_IN a_DT competing_VBG ligand_NN (_( 100_CD muM_NN mCPBG_NN or_CC 10_CD muM_NN MDL-72222_NN )_) ._SENT Kd_NN values_NNS were_VBD determined_VBN by_IN fitting_VBG the_DT binding_JJ data_NNS to_TO the_DT following_VBG equation_NN using_VBG GraphPad_NP PRISM_NP (_( San_NP Diego_NP CA_NP )_) :_: B_LS =_SYM Bmax_NP [_SYM L_NP ]_SYM n_NN /_SYM (_( [_SYM L_NP ]_SYM n_NN +_SYM Kn_NP )_) ,_, where_WRB theta_NN is_VBZ bound_VBN ligand_NN ,_, Bmax_NP is_VBZ the_DT maximum_JJ binding_NN at_IN equilibrium_NN L_NP is_VBZ the_DT free_JJ ligand_NN concentration_NN and_CC n_NN is_VBZ the_DT Hill_NP coefficient_NN ._SENT For_IN Ki_NP determinations_NNS ,_, 100_CD mul_NN of_IN homogenate_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD hours_NNS with_IN varying_VBG concentrations_NNS of_IN inhibitor_NN and_CC [_SYM 3H_NP ]_SYM granisetron_NN (_( NEN_NP ,_, MA_NP )_) ._SENT Binding_VBG was_VBD terminated_VBN by_IN rapid_JJ 